Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors

Trial Profile

Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2016

At a glance

  • Drugs CUDC 907 (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Curis
  • Most Recent Events

    • 31 May 2015 Interim results presented at ASCO 2015, per Curis media release.
    • 31 May 2015 Interim results published in Curis media release.
    • 24 Feb 2015 According to a Curtis media release, this study was initiated under a second Investigational New Drug (IND) application for CUDC-907 that was accepted by the U.S. Food & Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top